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Abstract. – OBJECTIVE: Infertile women re-
quiring ovarian stimulation and assisted repro-
duction techniques (ART) are faced with diffi-
cult issues. The fear that using hormones could 
increase their risk of cancer is the most signifi-
cant. One of the main challenges for assessing 
cancer risk after ART is the difficulty to separate 
it from the underlying condition of infertility per 
se. The delay or the inability to achieve a preg-
nancy is an important risk factor for breast, en-
dometrial and ovarian cancer. We analyzed the 
current literature on the topic. 
MATERIALS AND METHODS: The published 
literature in Medline and Cochrane was screened 
using the following keywords: ovulation induction, 
reproductive techniques, clomiphene, in vitro fertil-
ization, fertility agents, female/adverse effects, fe-
male/toxicity gonadotropins/ adverse effects or go-
nadotropins/toxicity and ”neoplasms or cancer”. 
RESULTS: A total of 95 articles were evaluat-
ed. Limited evidence suggests that high doses 
or many cycles of clomiphene citrate could in-
crease the risk of endometrial cancer, although 
the confounding factors of polycystic ovarian 
disease and overweight are not always consid-
ered. In some studies, ART modestly increased 
the risk of borderline ovarian cancer. Fertility 
treatments do not increase the risk of breast, 
cervical, endometrial and ovarian cancers, thy-
roid, melanoma and colon cancer. 
CONCLUSIONS: Women can be reassured 
that fertility drugs do not appear to significant-
ly increase the risk of invasive ovarian, endome-
trial, breast or other cancers, while achieving a 
pregnancy at an earlier age is a significant pro-
tective factor.
Key Words:
Fertility drugs, In-vitro fertilization, Ovarian stimula-
tion, Cancer risk, Breast cancer, Ovarian cancer, Gyneco-
logical cancer, Thyroid cancer, Melanoma, Colon cancer.
Introduction
Male and female infertility is increasing in 
the general population and more women are re-
lying on assisted reproduction techniques (ART) 
to conceive1. It is estimated that approximately 
1% of births worldwide are the result of ART, 
and most likely these numbers will increase, 
due to the socio-demographic trend to postpone 
pregnancy at later ages for personal and social 
reasons2. Conditions such as being overweight 
or obesity, excessive smoking, anovulation, en-
dometriosis and nulliparity are also on the rise, 
and besides being frequent causes of infertility 
they are also independently related to an in-
creased risk of cancer3. Moreover, the concern 
that drugs used for ovulation induction could 
increase the risk of estrogen sensitive breast and 
endometrial cancers by raising the levels of sex 
hormones is widespread in the general popula-
tion and among professionals. Mechanisms like 
multiple ovulation and ovarian trauma by oocyte 
retrieval are also believed to increase the risk of 
ovarian cancer. According to a recent systematic 
review and meta-analysis4 ART does not seem to 
be associated with elevated cervical, ovarian or 
endometrial cancer when the confounding effect 
of infertility is neutralized. However, there are 
still methodological reasons for example the lack 
of valid exposure data, the need to adjust for a 
variety of meaningful confounders and the lack 
of relatively long follow-up periods that need 
to be considered before sound conclusions can 
be drawn. The aim of this study is to assess the 
available evidence correlating ART with the risk 
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of developing cancer in the infertile population, 
after controlling for confounding factors that may 
introduce important biases. In order to give a 
more immediate message we considered together, 
for example, ovarian stimulation and ART. The 
main characteristics of the different treatments 
are summarized in Table I. 
Materials and Methods 
The published literature was screened using 
the following keywords: ((OVULATION IN-
DUCTION[TI] OR IVF[TI] OR “Reproductive 
Techniques, Assisted/adverse effects”[Mesh] OR 
clomiphene[ti] OR “in vitro fertilization”[ti] OR 
“Fertility Agents, Female/adverse effects”[Mesh] 
OR “Fertility Agents, Female/toxicity”[Mesh] 
OR “Gonadotropins/adverse effects”[Mesh] OR 
“Gonadotropins/toxicity”[Mesh] OR “Clomi-
phene/adverse effects”[Mesh] OR “Clomiphene/
toxicity”[Mesh]) AND (NEOPLASMS[MAJR] 
OR “Neoplasms/EPIDEMIOLOGY”[Mesh] OR 
Neoplasms/CHEMICALLY INDUCED[MH] OR 
cancer[ti] OR Breast Neoplasms/etiology[MA-
JR]) AND (REVIEW[PT] OR systematic[sb] OR 
guideline*)) NOT (“fertility preservation”[ti] OR 
Polycystic Ovary Syndrome/therapy[MH]) in 
Medline and the Cochrane. A total of 182 hits 
were found and 87 satisfied the inclusion criteria: 
peer reviewed papers, only published English 
literature, no abstracts, papers where the data of 
interest were clearly specified and collected. 
Results
We discuss the incidence of cancer in women 
undergoing ART. Most of the 87 papers analyzed 
focused on gynecological cancers (breast, en-
dometrium, ovary, cervix). Concerning gyneco-
logical cancers as a whole, the overall evidence 
is reassuring. In a review of 11 studies totaling 
3,900,231 patients of whom 118,320 were offered 
ART, the incidence of gynecological cancer in 
the ART-treated group was even lower (0.6%) 
than in the group not receiving ART (2.1%)5. 
Some of the studies, however, showed an in-
creased risk of cancer among certain sub-groups, 
such as women who received repeated treatment 
with clomiphene citrate6. It is, therefore, neces-
sary to monitor the long-term effects of infertility 
treatment on women’s health7. A possible increase 
in other cancers (thyroid, melanoma, colon and 
non-Hodgkin lymphoma) has also been inves-
tigated. Every woman may be particularly con-
cerned by a specific tumor; we, therefore, present 
evidence divided according to anatomical sites. 
Breast Cancer
Breast cancer is the most common and feared 
female malignancy, affecting one in eight women 
lifetimes. The causes of breast cancer are multi-
factorial and complex. Most are estrogen and pro-
gesterone sensitive and several hormonal aspects 
may influence breast cancer risk. These include 
both physiological conditions and pharmacolog-
ical treatments. Precocious menarche and/or late 
menopause, which result in a more prolonged 
exposure to estrogens, have been linked to an 
increased risk8, while pregnancies (especially at 
an early age) are protective possibly due to the 
prolonged exposure to natural progesterone. On 
the other hand, synthetic derivatives of proges-
terone are protective for the endometrium, but 
appear to be mitogenic on the breast9,10. Among 
pharmacological manipulations, both post-meno-
pausal hormone replacement treatment and the 
use of hormones for birth control have been 
associated with an increased incidence of breast 
cancer11-13. During fertility treatments, ovarian 
stimulation temporarily induces supra-physiolog-
ical estrogens levels, which also could theoreti-
cally increase the risk of breast cancer. However, 
the short period of time with high estradiol levels, 
even with multiple repetitive ovarian stimulation 
cycles, has not been shown to be a significant 
event for breast cancer risk. As ART use is in-
creasing, the interest for a potential oncogenic 
risk is becoming more relevant. This is biolog-
ically plausible; however, there are several con-
founding elements, which are considered risk fac-
tors for the development of breast cancer, such as 
infertility itself, nulliparity, delayed childbearing, 
and a later menopause, all of which are often not 
properly controlled for 14. There are also several 
aspects connected to the type of treatment ad-
ministered that may influence breast cancer risk: 
the drug(s) administered, the dose and schedule, 
the woman’s age and having achieved a full-term 
pregnancy or not. Even if most researches pub-
lished so far do not include analyses for these 
different confounders (since the numbers become 
progressively smaller making statistical infer-
ences less reliable) there are systematic reviews 
or meta-analyses describing breast cancer risk 
for specific treatments. All of these studies15-20 
have not found considerable differences in breast 
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Table I. Main differences among hormonal treatments that make their cancer risk not comparable.
 High endogenous Hormonal Menopausal Ovulation
 sex steroids  contraception therapy induction 
Effect of or  Overweight-obesity, Ovulation Inhibition Reduction of menopausal Multiple (or
Main purpose  sedentariety, early   symptoms, prevention of sometimes single) 
 menarche,   hypoestroestrogenism ovulation 
 late menopause   consequences induction 
Usual composition  Estradiol (E2) Mainly strong syntetic Very low dose natural Antiestrogens
 Progesterone (P)  progestogens with a estrogens and progesterone (clomiphene) or
  low dose of ethinil  or close to natural gonadotrophins
  estradiol or estradiol  progestogens  
Estradiol levels  High physiological in Progesterone suppressed Nowadays lower than High or very high
 premenopause, kept  and mostly substituted by premenopausal levels,  estradiol levels
 high after menopause low dose ethinilestradiol but sometimes continued produced by the
 (examp. obese);  or estradiol  many year after ovaries
   natural menopause  
Progesterone or Low or absent Completely inhibited Substituted by progesterone Natural
progestogens  (anovulation or and substituted by or the progestogen two weeks progesterone (or
 PCOS) the progestogen most month or all time time diidrogesterone)
 High in ovulating or all of the duration in continuous combined supplemented
 early menarche,  of treatment menopausal treatments 
 late menopausal     
Age and  Since puberty, higher Young or Postmenopausal, early Young not ovulating
usual condition  levels after weight  premenopausal menopause, or infertile or
 gain; usual lifetime usually hypoestrogenic needing 
 condition of most  ovulating or conditions superovulation
 female in industrialized not infertile  
 countries     
Duration of  Lifetime estradiol Months to many years Months to many years Usually some days
exposure or  exposure sometimes decades after menopause of supraphysiolgical
treatment  Two weeks monthly (expecially before first  estradiol exposure
 progesterone exposure full time pregnancy)   and two or few 
 in ovulation age in fertile age    more weeks of 
    progesterone after 
    ovulation induction 
Number and  Many large Many observational; Many, some RCT but Observational, 
quality of studies  epidemiological  no RCT  with E and P no more or  no RCT
   infrequently used in Europe  
Main risk  Estrogen or  Thrombotic  Thrombotic  Ovarian 
 progesterone sensitive   hyperstimulation 
 Cancers   syndrome, multiple
    pregnancies 
Breast cancer risk  Increased (obese Neutral (slightly Slightly increased with  Maybe neutral
 postmenopausal, early increased in E2+ syntetic progestogens;  
  menarche or late  older studies) maybe neutral with 
 menopause, sedentary  micronized P; reduced if 
  habits) Infertile   E2 only with Conjugated 
   Equine Estrogen  
Endometrial  Highly increased (obese, Greatly reduced Neutral to protective if Maybe neutral
cancer risk  early menarche or late   well  balanced E +P 
 menopause, sedentary    
 habits, anovulation)    
Ovarian Increased (obese, early Greatly reduced  Neutral or maybe Maybe neutral
cancer risk  menarche or late  slightly increased 
 menopause, sedentary   
 habits, infertile)   
Effect of giving Advise that following Countereffective Not effective if properly Not effective or
up treatment  or not the code against (overall cancer use (global cancer risk, countereffective
 cancer rules is far more risk is reduced health and mortality not (pregnancy or
 important than any  in hormonal affected or reduced in earlier pregnancy
 fertility drug effect  contraception users) younger users)  reduce female 
    cancer risk) 
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cancer risk in patients undergoing ART when 
compared to either untreated infertile women 
or with the general population21. 19.158 women 
who underwent IVF treatment and 5.950 women 
who started other fertility treatments were in-
cluded in a historical cohort22. After a follow-up 
lasting on average 21 years, IVF treatment was 
not associated with an increased risk of breast 
cancer compared to non-IVF fertility treatment. 
There was no increase in the risk of breast cancer 
in IVF patients compared to either the general 
population (SIR: 1.01, 95% CI 0.93-1.09) or to 
patients receiving non-IVF-related fertility treat-
ments (hazard ratio: 1.01, 95% CI 0.86-1.19). In 
a cohort study regarding infertile women, breast 
cancer incidence was not statistically different 
in women treated with IVF vs. untreated women 
(HR 1.10, 95% CI 0.88-1.36)23. A recent large 
meta-analysis24 of 8 cohort studies that included 
1,554,332 women and 14.961 breast cancer cases 
demonstrated no increased risk of breast cancer 
in IVF patients vs. the general population (RR: 
0.91, 95% CI 0.74-1.11) nor vs. the infertile female 
population (RR: 1.02, 95% CI 0.88-1.18). A cohort 
study of 12.193 infertile women followed for 30 
years25 found no increased risk of breast cancer 
after clomiphene citrate (hazard ratio: 1.05, 95% 
CI 0.9-1.22) or gonadotropins (hazard ratio: 1.14, 
95% CI 0.89-1.44) exposure compared to infertile 
controls. Breast cancer is more frequent after 
menopause and ovarian stimulation might cause 
an increase in the incidence at a later age. For this 
reason, the length of follow-up may introduce a 
bias and affect results on cancer incidence after 
ART. Investigations with a relatively short fol-
low-up may not capture an increase because this 
incidence tends to be manifested at a different 
age. Studies with a longer follow up (more than 
10 years) show a greater breast cancer risk24,25 
while no association was found in two studies 
with a very long follow-up. In two cohort studies 
involving a very long follow-up (30 years), the 
usage of fertility drugs did not increase breast 
cancer risk (HR 1.05, 95% CI 0.90-1.22) and 
(HR 1.14, 95% CI 0.89-1.44)25. Similar reas-
suring results were reported for different types 
of ovulation induction drugs: clomiphene citrate 
(SIR 1.21, 95% CI 0.91-1.58), gonadotropins (SIR 
0.4, 95% CI 0.11-1.6), or both (SIR 0.93, 95% CI 
0.48-1.63) when compared to the general popu-
lation14. Clomiphene citrate induces apoptosis in 
breast cancer cell lines in vitro26 and tamoxifen 
reduces breast cancer risk, when administered 
continuously27. A high cumulative number (more 
than six) of clomiphene citrate cycles seems to 
increase the risk of breast cancer14,25. In a more re-
cent study28 there was no dose response relation-
ship for CC and breast cancer and an increased 
risk of breast cancer was found in parous women 
(1.26 (95% CI 1.03, 1.54)) (p = 0.02) only. The 
possible breast cancer effect of gonadotropins 
could be mediated by the relevant increase in 
estrogens and progesterone. Estrogens stimulate 
the growth of breast cancer, but at high doses they 
are also an effective treatment for this disease. 
This has been termed the ‘estrogen paradox’. The 
supraphysiological levels achieved in ART could, 
therefore, be protective and not necessarily detri-
mental due to apoptosis induced by estrogens via 
the ERα receptor29.
Beginning ART treatment at a younger age 
correlates to an increased breast cancer risk14,18,23. 
Other studies show different data concerning age 
at first infertility treatment with regards to breast 
cancer risk30,31, cumulative dose of CC32 or hor-
monal cause of infertility14. In the study by van 
den Belt-Dusebout et al22, also after a follow-up 
lasting on average 21.1 years, the risk of breast 
cancer in IVF-treated women was notably dif-
ferent compared to that of the general population 
(SIR, 1.01 [95% CI, 0.93-1.09]) and to that of the 
non-IVF group (HR, 1.01 [95% CI, 0.86-1.19]). 
Likewise, it was considerably lower for women 
who had 7 or more IVF cycles (HR, 0.55 [95% CI, 
0.39-0.77]) compared to 1 to 2 IVF cycles and al-
so after an insignificant response to the first IVF 
cycle (HR, 0.77 [95% CI, 0.61-0.96] for <4 vs. ≥ 
4 collected oocytes). The extensive search for a 
possible association between ovarian stimulation 
and an increased risk of breast cancer failed to 
document it. Therefore, infertile patients can be 
reassured. However, continued follow-up includ-
ing the adoption of new protocols and drugs such 
as aromatase inhibitors, is recommended. In con-
clusion, there is Grade B evidence with regards to 
the lack of association of fertility drugs for ART 
and breast cancer. A very large analysis33 did not 
find any increase in breast cancer incidence (SIR 
0.98, C.I., 0.94 to 1.01) despite an excess of breast 
cancer in in situ SIR 1.15, C.I. 1.02 to 1.29). As 
proposed by ASRM34, patients can be reassured 
that fertility drugs are not associated with an in-
creased risk of breast cancer.
Endometrial Cancer 
Endometrial cancer is the most frequent gyne-
cologic malignancy and its incidence increases 
with age. Type I endometrial cancer is hor-
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mone-dependent, with prolonged unopposed es-
trogens considered as high risk, while progester-
one as having a protective effect. Endometrial 
cancer is also observed as a side effect of pro-
longed tamoxifen treatment for breast cancer35,36. 
Given its hormonal susceptibility, it is plausible 
to enlist endometrial cancers among those whose 
incidence may be increased by ovarian stimula-
tion for ART. Several studies have examined the 
relationship between endometrial cancer and the 
use of fertility medications, but the results are 
discordant. These studies are often limited by a 
small sample size, a short follow-up, and by sev-
eral confounding factors such as the choice of the 
reference population, the age at which treatment 
was administered, the dose used, the number of 
cycles, the underlying diagnosis of infertility like 
ovulatory dysfunction, obesity or polycystic 
ovarian syndrome (PCOS) or other methodologi-
cal limitations37. Overall, most studies showed 
that the use of fertility drugs was not associated 
with a significant increased risk for endometrial 
cancer. A study with a very long follow-up (26 
years)37 of a cohort of 12.193 women did not find 
an increased risk of breast cancer with clomi-
phene (HR 1.39, 95% CI 0.96-2.01), gonado-
tropins (HR 1.34, 95% CI 0.76-2.37), or both (HR 
1.77, 95% CI 0.98-3.19). In addition, no increased 
incidence has been observed in a large recent 
longitudinal cohort study that evaluated the short-
term risk of cancer among women of reproduc-
tive age undergoing ART treatments38. Women 
treated with ART had a statistically significantly 
lower risk for all cancers (for all women: SIR 
0.78; CI, 0.73-0.83; women without prior ART: 
SIR 0.75; CI, 0.68-0.82), breast cancer, and all 
female genital cancers. In this study on 113,226 
American women there was also a non-statistical-
ly-significant lower risk for endocrine and uter-
ine cancer; and a non-statistically-significant 
higher risk for melanoma and ovarian cancer. A 
population-based cohort study including all wom-
en registered in the Medical Birth Registry of 
Norway did not find a global significant correla-
tion, after correcting for multiple analyses24, but 
clomiphene citrate only was associated with in-
creased risk of ovarian and endometrial cancer. A 
meta-analysis39 of six studies comprising 776,224 
infertile patients, of whom 103.758 receiving fer-
tility treatments, did not find an increased risk of 
endometrial cancer between treatment vs. 
non-treatment (odds ratio: 0.78, 95% CI 0.39-
1.57). Another meta-analysis4 found that women 
undergoing ART had a higher risk for endometri-
al cancer (RR 2.04, 95% CI 1.22-3.43). Compared 
to an untreated infertile cohort, the risk was not 
significant and even seemed reduced (RR 0.45, 
95% CI 0.18-1.14). Therefore, infertility per se 
and not its therapy seems to be the main risk fac-
tor for endometrial cancer. A study on 2.431 
women, who were followed for over 20 years, 
showed that the risk of endometrial cancer did not 
increase compared to the general population ei-
ther with CC (SIR 1.07, 95% CI 0.39-2.33) or hu-
man menopausal gonadotropin (hMG) (SIR 2.16, 
95% CI 0.43-6.32). In addition, the initial higher 
risk (SIR 5.0, 95% CI 2.15-9.85) was no longer 
significant in a subsequent multivariate reanaly-
sis14. The recent analysis of a large population33 
also did not find any increased risk (SIR 1.12, 
95% C.I. 0.95 to 1.30). Older analyses40 reported 
a higher risk of endometrial cancer in infertile 
patients vs. the general population, with age at 
first use <30 years and last use less than 25 years 
(OR 3.26, 95% CI 1.07-9.95). However, no infor-
mation with regards to the kind of fertility drugs 
used was provided. Endometrial cancer risk was 
shown in infertile women with ovulatory dys-
function, progesterone deficiency, and/or obesi-
ty41,42. Some data seem to indicate clomiphene as 
a risk factor. A registry-based cohort study28 
found an increased risk of endometrial cancer in 
women receiving clomiphene citrate (hazard ra-
tio: 2.91, 95% CI 1.87-4.53), but not in women 
undergoing IVF (hazard ratio: 1.62, 95% CI 0.70-
3.85) compared to the general population. This 
study, however, was limited by a lack of adjusting 
for confounding factors. According to the latest 
Cochrane review43 to the use of clomiphene ci-
trate in infertile women, it might increase endo-
metrial cancer risk, especially in cumulative dos-
es greater than 2000 mg and after a high number 
of cycles (more than 7). The reason for this in-
creased incidence may be the presence of con-
founding factors, such as overweight or polycys-
tic ovary syndrome, found in women who require 
treatment with CC, but the evidence at present 
available in the literature is actually not adequate 
to reach any solid conclusion. Data regarding ex-
posure to gonadotropins were also inconclusive. 
Cochrane data analyzed more in detail reveal that 
six studies, that included infertile women and not 
a general population control group, established 
that exposure to ovary stimulating drugs did not 
result in an increased risk of endometrial cancer 
(RR 0.96, 95% CI 0.67 to 1.37; 156.774 partici-
pants; evidence of very low quality). The risk was 
found to be increased in fifteen studies in women 
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exposed to any ovary-stimulating drug (RR 1.75, 
95% CI 1.18 to 2.61; 1.762.829 participants; evi-
dence of very low quality) where the general 
population was used as the control. Five studies, 
limited to infertile women (92.849 patients), re-
ported on the exposure to clomiphene citrate; 
there was a positive association (RR 1.32; 95% CI 
1.01 to 1.71; 88.618 participants; evidence of very 
low quality), but only at a high dosage (RR 1.69, 
95% CI 1.07 to 2.68; two studies; 12.073 partici-
pants) and with a high number of cycles (RR 1.69, 
95% CI 1.16 to 2.47; three studies; 13.757 partici-
pants). Four studies reported an increased risk of 
endometrial cancer in women who needed clomi-
phene citrate compared to the general population 
(RR 1.87, 95% CI 1.00 to 3.48; four studies, 
19.614 participants; evidence of very low quality). 
In these researches, anyway, it was not possible to 
determine if the association was due to the patho-
logical conditions that requested clomiphene 
treatment or to the drug. When infertile women 
not treated with any stimulating agent were used 
as the reference, it was possible to observe that 
gonadotropins increased the risk of cancer of the 
endometrium (RR 1.55, 95% CI 1.03 to 2.34; four 
studies; 17,769 participants; evidence of very low 
quality). By analyzing two works (1595 partici-
pants) which used the general population as a 
reference group, it was possible to find that there 
was no variation in risk (RR 2.12, 95% CI 0.79 to 
5.64: evidence of very low quality). The use of 
both clomiphene citrate and gonadotropins result-
ed in no relevant difference in endometrial cancer 
risk compared to unexposed infertile women (RR 
1.18, 95% CI 0.57 to 2.44; two studies; 6345 par-
ticipants; evidence of very low quality). However, 
a higher risk was found when compared to the 
general population, indicating that the key factor 
may be infertility, and not its treatment (RR 2.99, 
95% CI 1.53 to 5.86; three studies; 7789 partici-
pants; evidence of very low quality). Infertile 
women who are overweight and obese with oligo-
menorrhea due to PCOS should be informed to be 
at increased risk for endometrial cancer and ad-
vised to adopt lifestyle changes to reduce their 
risk, such as weight loss and adequate endometri-
al protection with progesterone or progestogens. 
Clomiphene citrate and lately the aromatase in-
hibitor letrozole are first line treatments for up to 
12 cycles for women with World Health Organi-
zation Group II ovulation disorders (hypothalam-
ic pituitary dysfunction), such as PCOS, as rec-
ommended by contemporary guidelines44,45. Ac-
cording to the ASRM guidelines (grade B evi-
dence), patients can be reassured that the in-
creased risk of endometrial cancer is not linked to 
fertility drugs. Ovulatory PCOS infertile patients 
should be educated about healthy lifestyle chang-
es: weight loss and exercise to reduce the under-
lying risks for endometrial cancer. 
Epithelial and Stromal Ovarian Cancer
Ovarian cancer is a complex disease that in-
cludes at least five different histological types, 
thus any study relating to ovarian cancer has 
some limits. High-grade serous cancer (which 
is the most common type often identified with 
“ovarian cancer”) generally appears after meno-
pause and it is usually diagnosed at a late stage, 
since screening with imaging techniques and/or 
serological analyses has a limited efficacy46. This 
cancer has a poor prognosis and so any impact 
of ART could be relevant. Protective factors are 
multi-parity, breastfeeding and oral contracep-
tives (not frequently used in infertile patients). 
Independently of treatment for fertility issues, 
women with family history or genetic suscep-
tibility to ovarian cancer, infertility and nulli-
parity, and late menopause, have an increased 
risk of developing invasive ovarian cancer47,48. 
When examining the relationship between the 
use of fertility medications and ovarian cancer, 
these confounding variables must, therefore, be 
considered. Long-term follow-up is necessary as 
ovarian cancer typically occurs after menopause. 
Ovulation has been proposed as a potential cause 
of ovarian cancer; therefore a potential promoting 
effect of fertility drugs is plausible. Incessant 
ovulation theory states that factors decreasing 
lifetime ovulation rates, such as multiparity or 
combined hormonal contraception, reduce ovar-
ian cancer risk49. Conversely, the use of fertility 
medications could increase ovarian cancer risk 
by promoting multi follicular ovulation46, thus 
increasing mechanical trauma and the quantity 
of epithelial inclusions of the ovarian surface 
epithelium. 
It has been calculated, although inevitably in a 
very approximate way, that the hormonal stimu-
lation used for a single cycle of IVF results in the 
production of a number of follicles and in an es-
trogen exposure similar to what occurs in two 
years of life50. Furthermore, the risk of ovarian 
cancer has not decreased but augmented in wom-
en with anovulation, ovulatory disturbances, or 
infrequent ovulation, whereas in accordance with 
the ‘incessant ovulation’ theory, the risk of ovar-
ian cancer would have expected to be reduced in 
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these women48. It is also possible to hypothesize 
that in the absence of pregnancy the risk of ovar-
ian cancer is already increased before ART. An 
explanation is that an underlying ovulatory disor-
der, or that the fact that the woman does not be-
come pregnant , are themselves causes of can-
cer51. High doses of gonadotropins may have a 
predisposing effect directly or through the in-
creased level of estrogens52-54. Nevertheless, these 
data do not prove the existence of a causal rela-
tionship between iatrogenic elevation of serum 
gonadotropin concentrations and the develop-
ment of granulosa cell tumors. Other explana-
tions are possible, such as the presence of the tu-
mor before fertility treatment initiation, or that 
the onset of the tumor during fertility treatment 
was coincidental. This role of gonadotropins is in 
accordance with the protective effects of preg-
nancy and oral contraceptives. An additional hy-
pothesis is that undiagnosed early ovarian cancer 
can cause infertility. The basis of this suggestion 
was observed in the epidemiological data indicat-
ing that patients with ovarian cancer had a higher 
rate of infertility55. As a result of recent theo-
ries56,57 stating that epithelial ovarian cancer orig-
inates in the fallopian tubes and not in the ovary 
itself, a currently accepted treatment for women 
with severe tubal disease is salpingectomy before 
IVF. Older researches55,58 indicated that ovarian 
cancer may be increased by ART. In some of 
these works, however, methodological aspects 
may have played a role: in some cases the refer-
ence population consisted of women in the gener-
al population, not of untreated infertile women 
which represent a group more suitable for com-
parison. In other researches the absolute number 
of cancers was low, while in others malignant and 
benign tumors were considered together. Unpre-
dictable elements, such as the imprecise record-
ing of medications and the duration of treatment, 
make these studies largely unreliable. And it must 
be considered that in the last years ovarian stim-
ulation protocols have changed and do not resem-
ble those used in some of these reports59. Analy-
ses38,60 conducted and published in the last years 
do not support the idea that ART may be linked 
to a higher risk of malignant invasive cancer. 
More in detail ovarian cancer risk is not increased 
in premenopausal women undergoing ART24. 
Similar conclusions were reached by reviews and 
meta-analyses4,16,61-64 that evaluated the epidemi-
ology of ovarian cancer and found no increase in 
its incidence. In more than 87,000 women, ovari-
an cancer was not increased by any treatment for 
infertility (hazard ratio [HR] 0.90, 95% CI 0.45-
1.79) nor by IVF (HR 1.58, 95% CI 0.75-3.29)37. 
According to a cohort study65, which included 
more than 54,000 infertile women with an aver-
age follow-up period of 16 years, invasive ovarian 
cancer did not increase with the use of CC (ad-
justed rate ratio [ARR] 1.14, 95% CI 0.79-1.64) or 
gonadotropin (ARR 0.83, 95% CI 0.50-1.37) com-
pared to women who never used them. The larg-
est systematic review, which included 11 
case-control and 14 cohort studies, was published 
by the Cochrane Collaboration66 and consisted of 
182.972 women. Due to a very high heterogeneity 
among studies, it was impossible to obtain an 
overall relative risk. Women treated for infertility 
with any drug did not have an increased risk of 
invasive ovarian cancer: this was observed in 
cohort- and in case-control studies that analyzed 
women of a similar age, or untreated infertile 
women, as the reference group. When, in cohort 
studies, comparison was made with the general 
population invasive ovarian cancer incidence was 
more frequent. In one study SIR was 5.0 (95% 
confidence interval (CI) 1.0 to 15), but this was 
due to the occurrence of a very low number of 
cancers (three) and risk was lower when cancers 
diagnosed in the first year after treatment were 
not included (SIR 1.67, 95% CI 0.02 to 9.27). 
However, another study67 on 26 cases showed an 
OR of 2.09 (95% CI 1.39 to 3.12). A long-term 
follow-up of a historical cohort in Sweden report-
ed no overall excess risk of invasive ovarian can-
cer emerged compared with the general popula-
tion68. Considering borderline ovarian tumors, 
some case-control studies found an increased risk 
after fertility drug treatment. One of these studies 
reported an OR of 28 (95% CI 1.5 to 516) but this 
was based on the occurrence of four cancers69. In 
a cohort study70, the hazard ratio (HR) for a bor-
derline ovarian tumor was 4.23 (95% CI 1.25 to 
14.33) for infertile women treated with IVF com-
pared to a non-IVF treated group who had a fol-
low-up lasting over one year. There was no proof 
that the risk increased in women exposed to clo-
miphene alone or clomiphene plus gonadotropin, 
compared to untreated women. Risk was high 
during the first year after the IVF, which may be 
supported by the reported evidence that ovarian 
stimulation may induce growth in existing highly 
differentiated tumors16. One case-control study 
stated that the risk increased in users of human 
menopausal gonadotrophin (HMG) (OR 9.4, 95% 
CI 1.7 to 52). However, this estimate was based on 
only six cases. The conclusion of the Cochrane66 
Risk of cancer after assisted reproduction: a review
8049
reported no conclusive evidence of an increased 
risk of ovarian cancer for women who are treated 
with fertility drugs, compared to infertile women 
not treated with fertility drugs, or to women in 
the general population. Of note, five studies 
showing an increase in the risk of ovarian cancer 
were of low methodological quality and subse-
quently their results are not reliable to conclude 
that the risk of cancer is definitive while on treat-
ment for infertility. In one study that included 
over 25,000 women, the risk of ovarian cancer 
increased only when the follow-up was extended 
to more than 15 years (SIR 3.54, 95% CI 1.62-
6.72). The analysis of the entire patient group 
showed no increase of invasive ovarian cancer 
when compared to the general population (stan-
dardized incidence ratio [SIR] 1.30, 95% CI 0.86-
1.88)70. A higher risk of ovarian cancer after fer-
tility drugs (SIR 1.91, 95% CI 1.18-2.91) had been 
used was shown in another investigation. Howev-
er, with the exclusion of cancer cases, which had 
been diagnosed within one year of receiving 
treatment, this increase was no longer significant 
(SIR 1.46, 95% CI 0.83-2.36)67. A popula-
tion-based cohort study that included 106.031 
women followed for a period lasting on average 
12 years, showed that history of IVF treatment 
remained independently associated with ovarian 
and uterine cancer after controlling for confound-
ing variables such as maternal age and obesity 
[hazard ratio: 3.9, 95% CI 1.2-12.6], but this oc-
curred over a 25-year period during which fertil-
ity drug use changed and it was based on only 
three women with invasive ovarian cancer fol-
lowing IVF71. The majority of data indicate that 
ovarian cancer risk comes from infertility per se 
and Brinton et al37 did not find an association 
between ovarian cancer and fertility treatment 
when using infertile women as control group, 
even for women who had undergone at least four 
cycles of IVF. A meta-analysis 4 of nine cohort 
studies including 109.969 patients compared the 
ovarian cancer risk in women receiving fertility 
treatment with that in an infertile reference group 
and the general population. The risk of ovarian 
cancer in women receiving fertility treatment in-
creased compared to the general population [rela-
tive risk (RR): 1.50, 95% confidence interval (CI) 
1.17-1.92], but was similar to that of the infertile 
reference group (RR: 1.26, 95% CI 0.62-2.55). A 
recently published analysis33 on a huge population 
(2.2 million person years of observation) did find 
an increased risk of ovarian cancer, both invasive 
(SIR 1.40, C.I. 1.24 to 1.58) and borderline (SIR 
1.36, C.I. 1.15 to 1.60). The very interesting ob-
servation is that ovarian cancer increased only in 
women with conditions associated with ovarian 
cancer (low parity and/or endometriosis).
Risk of Ovarian Cancer due 
to Individual Fertility Drugs
Most studies could not find dissimilarity in 
the incidence of ovarian cancer according to 
the specific type of fertility drugs, whether anti 
estrogens or gonadotropins, utilized. The largest 
study, which focused on the risk of cancer linked 
specifically to fertility drug usage, examined data 
on all the women who were followed in Dan-
ish fertility clinics during the years 1963-199865. 
Women who were treated with gonadotropins 
(risk ratio [RR] 0.83, 95% CI 0.50-1.37), CC (RR 
1.14, 95% CI 0.79-1.64), hCG (RR 0.89, 95% 
CI 0.62-1.29), or gonadotropin-releasing hormone 
(GnRH agonist (RR 0.80, 95% CI 0.42-1.51), 
either individually or when combined, demon-
strated no overall increase in the risk of devel-
oping epithelial ovarian cancer. Furthermore, it 
was not possible to make any associations with 
the quantity of cycles of use, parity, or duration 
of follow-up. Reigstad el al28 showed that wom-
en failing to conceive after clomiphene citrate 
therapy, have a higher risk of ovarian cancer 
warranting further investigation of this subgroup 
of women28. Trabert et al72 which included 9.825 
women who were referred for infertility, found 
that the risk for invasive ovarian cancer follow-
ing the utilization of gonadotropins or CC did 
not increase, except for 517 women who were 
still childless after the use of CC (RR 3.63, 95% 
CI 1.36-9.72). Other investigations14,68,73-75 did not 
find that a risk for ovarian cancer increased with 
the use of CC, gonadotropins, combined therapy, 
or other drugs for infertility. In conclusion, the 
overwhelming majority of reports did not find a 
significant effect on ovarian cancer risk after the 
exposure to any specific fertility drug. 
The Special Case of BRCA 
Mutation Carriers
Fertility treatments for carriers of BRCA mu-
tation should not be restrained or viewed as 
capable of modifying the risk for invasive epithe-
lial ovarian cancer as this high-risk group may 
also be more likely to undergo fertility treatment 
whether for fertility preservation or diminished 
ovarian reserve. A recent matched case-control 
study (941 pairs with and without a diagnosis 
of cancer)76 assessed the risk of ovarian cancer 
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in BRCA mutation carriers undergoing fertility 
treatment and found no significant relationship 
between fertility medication use and subsequent 
risk of ovarian cancer. Another cohort study77 of 
1,073 BRCA mutation carriers showed no asso-
ciation between fertility treatment and ovarian 
cancer, regardless of type of fertility treatment 
in the 164 (15%) patients that received fertility 
treatment in both BRCA1 and BRCA2 mutation 
carriers. These studies, even if relatively small in 
size, are reassuring. 
Borderline Ovarian Tumors
Borderline ovarian tumors have a low ma-
lignant potential and represent about 15% of all 
ovarian cancers, with a 1.8-4.8 incidence per 
100,000 women years78. They are noninvasive, 
indolent tumors that differ from invasive ovari-
an cancer in having an excellent diagnosis with 
a 95% 5-year rate of survival. They are more 
common in reproductive-aged women who have 
not been associated with parity, endometriosis 
or prior surgery, so they behave differently from 
invasive cancers. Some studies showed an in-
crease in the risk of borderline ovarian tumors 
in infertile women who were treated using IVF. 
A large study23 evaluated a cohort of infertile 
patients selected on the basis of a hospital reg-
istry and evaluated cancer incidence in women 
who underwent IVF including as a reference 
population infertile patients who did not use 
IVF. 17 women out of the 7,544 who underwent 
IVF were diagnosed with borderline ovarian 
tumors, whereas 14 cases were identified in 
14,095 women who did not use IVF. Women 
undergoing IVF showed a higher borderline rate 
of ovarian tumors with an HR of 2.46 (95% CI 
1.20-5.04), which indicates 11 additional tumors 
(borderline) per 10,000 women. The incidence 
was not affected by hysterectomy, endometrio-
sis, sterilization or prior birth, which is in con-
trast to invasive ovarian cancer. Van Leeuwen 
et al70 compared borderline ovarian tumors in 
more than 19,000 women undergoing IVF with 
6,000 infertile women who did not use IVF 
and with the general population. After an av-
erage of 14.7-year follow-up and after adjusting 
for age, parity and fertility diagnosis, the risk 
of borderline ovarian tumors was increased in 
treated women (SIR: 1.79, 95% CI 1.16-2.56). 
Another cohort study23 also found an increased 
rate of borderline ovarian tumors in women who 
received IVF, after controlling for confounders 
(hazard ratio: 2.66, CI 1.2-5.04). Three cohort 
and three case-control studies were identified 
through the largest review which evaluated bor-
derline ovarian tumor risks after fertility drugs 
were used66. Three researchers47,69,79 described 
an increase in borderline ovarian tumors with 
the use of a fertility drug: this consisted of a 
2- to 3-fold excess. A true meta-analysis was 
not possible because of the excessive hetero-
geneity among findings. However, in the eval-
uation of individual drugs, the increase in risk 
for borderline ovarian tumors with CC alone, 
CC and gonadotropins, or gonadotropins alone 
was not significant. An increase in the risk of 
borderline ovarian tumors using fertility drugs 
has not been shown by some investigations80. 
The largest study addressing this question81 was 
a retrospective case-cohort study of 96,545 in-
fertile Danish women observed for an average 
of 11 years. 142 women had borderline ovarian 
tumors but the risk did not increase with fertility 
drugs use (RR 1.0, 95% CI 0.67-1.51). Though 
there was no association observed for CC, go-
nadotropins, hCG, or GnRH agonists, the risk 
of the increase of borderline tumors was asso-
ciated with the use of progesterone (RR 1.82, 
95% CI 1.03-3.24). However, the absolute risk 
was extremely small, given the low incidence of 
this disease. Despite possible surveillance bias, 
most borderline ovarian tumors have been diag-
nosed up to 7-9 years after fertility treatment, 
raising concern about such an association since 
there is a high general risk of bias: retrospective 
study design, a lack of accounting for potential 
confounding and estimates which are based on a 
minor number of cases. In conclusion, based on 
the available evidence, infertile patients may be 
reassured since there appears to be no signifi-
cant increase in the risk of invasive ovarian can-
cer after fertility drug usage. (Grade B evidence, 
ASRM28) and the risk is not different for any 
specific treatment (Grade B evidence, ASRM). 
When considering borderline ovarian tumors, 
the higher risk remains an open question. A 
small increase has been shown through several 
studies but the data remains insufficient (Grade 
C evidence, ASRM). It must be stated, however, 
that these are generally indolent tumors and car-
ry a relatively good prognosis. Further studies 
are definitely needed. 
Cervical Cancer
A number of studies4,24,28,71, which assess cer-
vical cancer risk following the use of fertility 
medication, have consistently shown that risk 
Risk of cancer after assisted reproduction: a review
8051
does not increase in comparison to both the gen-
eral population and infertile patients. A subset of 
researches37,82 found that IVF patients showed a 
decrease of cervical cancer, although the mech-
anism behind this phenomenon is unclear and is 
perhaps related to better access to care with more 
frequent cervical cytology screening in women 
undergoing fertility treatment. 
In conclusion, there is reasonable proof that 
an increase in the risk of cervical cancer is not 
associated with fertility drugs (Grade B evidence, 
ASRM).
Thyroid Cancer
The incidence of thyroid cancers is not asso-
ciated with ART treatments as reported in most 
papers 75,83. An increase in the risk of thyroid 
cancer is observed in association with high parity 
and use of exogenous hormones (hormone re-
placement therapy and oral contraceptives)84. In 
a retrospective cohort of 8.422 women evaluated 
for infertility41, neither clomiphene citrate (RR: 
1.42, 95% CI 0.5-3.7) nor gonadotropin (RR: 
1.1; 95% CI 0.2-4.9) demonstrated an increased 
risk of thyroid cancer (18 cases) (RR: 1.42; 95% 
CI 0.5-3.7). It is possible that clomiphene citrate 
use may have a stronger effect on thyroid cancer 
risk among women who remain nulliparous (RR: 
4.23; 95% CI 1.0-17.1), although six out of 18 
thyroid cancer cases in this work were missing 
parity data. Another recent retrospective cohort 
study85 showed a non-significant increase in thy-
roid cancer risk with the use of clomiphene citrate 
(hazard ratio: 1.57; 95% CI 0.89-2.75), based on 
55 cases of thyroid cancer in a cohort of 9,892 
women. Thyroid cancer risk was greatest among 
those women who received more than 2,250 mg 
of clomiphene citrate (hazard ratio: 1.96; 95% CI 
0.92-4.17), although gonadotropin administration 
was unrelated to increased risk (hazard ratio: 
1.16; 95% CI 0.52-2.58). A Danish cohort study 
of 54,362 infertile women86 showed a significant 
association between CC use and thyroid cancer, 
based upon 29 cases (RR: 2.29; 95% CI 1.08-
4.82). This increased risk was primarily associat-
ed with CC use in parous women. An increased 
risk of thyroid cancer was not found after gonad-
otrophin use (RR: 1.43; 95% CI 0.54-3.83), but 
was observed following progesterone use (RR: 
10.14; 95% CI 1.93-53.34), although only in two 
patients. In conclusion, there is insufficient evi-
dence to suggest an association between fertility 
medication use and thyroid cancer and only some 
studies show that thyroid cancer could be related 
to clomiphene use. On the whole, there seems to 
be no effect of fertility drugs on invasive thyroid 
cancer risk (Grade B evidence, ASRM).
Melanoma
Most works41,87 have not shown that the risk 
of melanoma increases with the use of fertility 
drugs. There has been in the last years an in-
crease in the occurrence of malignant melanoma, 
particularly in women, and this has been linked 
to late age at first birth, low parity and to oral 
contraceptives88. Stewart et al89 found that women 
giving birth following IVF had an increased rate 
of invasive melanoma vs. women who failed to 
conceive after IVF, based on 139 invasive mela-
noma cases (hazard ratio: 3.61; 95% CI 1.79-7.26). 
There was, however, no increased risk in wom-
en receiving non-IVF-related fertility treatment 
(hazard ratio: 1.39; 95% CI 0.88-2.20). Hannibal 
et al88 showed that fertility treatment was not as-
sociated with malignant melanoma, except for an 
increased risk following use of gonadotrophins or 
gonadotropin-releasing hormone in parous wom-
en. Finally, the use of clomiphene citrate has 
been associated with increased risk of melanoma 
in some73,85 but not all88,90 studies. In conclusion, 
there is not enough evidence to suggest an as-
sociation between fertility drugs and melanoma 
(Grade C evidence, ASRM).
Colorectal Cancer
There is insufficient evidence to suggest an 
association between fertility medication use and 
colon cancer. In a large cohort study41, clomi-
phene citrate use did not significantly increase the 
risk of colon cancer (RR: 0.83; 95% CI 0.4-1.9). 
In a retrospective cohort study of 9,892 women 
followed for a median of 30 years that detect-
ed 91 colorectal cancers, clomiphene citrate use 
was unrelated to colorectal cancer risk (hazard 
ratio: 0.82; 95% CI 0.52-1.30)85. A cohort study 
in 19,158 women who underwent ovarian stimu-
lation for IVF compared to two groups (women 
who received different fertility treatments and 
the general population) found 109 colorectal can-
cers after a 21-year follow-up. The risk of colon 
cancer for the IVF group did not increase com-
pared to the general population (SIR: 1.00; 95% 
CI 0.80-1.23), however, non-IVF women had a 
reduced risk (SIR 0.58, 95% CI 0.36-0.88)91. 
In conclusion, there is reasonable evidence that 
there is no association between fertility drugs and 
an increase in the risk of colon cancer (Grade B 
evidence, ASRM).
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Non-Hodgkin Lymphoma
Calderon-Margalit et al73, evaluating the risk 
for non-Hodgkin lymphoma following fertility 
drug usage, showed that the risk increased with 
ovulation induction therapy (HR 2.86, 95% CI 
1.14-7.20) but not with use of only CC. However, 
there is insufficient data to make any conclusion, 
although ART does not seem to have an associ-
ation with an increase in the risk of lymphoma 
(Grade C evidence according to ASRM).
Conclusions
We reviewed the available literature on cancer 
risk in women undergoing ART: we tried to focus 
on the most relevant studies in terms of size and 
quality of the analysis. Further, we put them into 
proper perspective and tried to make the infor-
mation available to readers through simple tables, 
focused on patient counseling. At the same time 
we included trials with discordant results to show 
that this question is far from being settled. Many 
confounding elements may explain the differ-
ences reported. Women considering ART should 
receive balanced and sound advice but no over-
simplification. High estrogens levels may theo-
retically increase the risk of hormone dependent 
cancers: breast, endometrium, and ovary. There 
is a relationship between long lasting high circu-
lating estrogen levels (notably after menopause) 
and breast cancer. However, the cancer effect of 
fertility drugs is very different from that of en-
dogenous hormones, hormonal contraception or 
menopausal therapy92. This applies specifically 
to a possible link between endogenous estrogens 
and the risk of premenopausal breast cancer: 
data are unfortunately scanty and results are not 
always plausible92. After reviewing the available 
literature, infertile women may be at an increased 
risk of invasive ovarian, endometrial, and breast 
cancer; however, the use of fertility drugs does 
not appear to increase this risk34. Methodological 
limitations need to be considered and studied fur-
ther before drawing definitive conclusions. These 
are duration of infertility treatment, which is very 
short compared with the average use of hormonal 
contraception or menopausal hormonal therapy, 
and conditions like obesity that increase endoge-
nous sex hormones causing very long lasting and 
measurable effects on susceptible reproductive 
organs. The putatively ART-related cancers may 
occur many years from the usual age of ART 
treatments, making it difficult to determine a 
cause-effect relationship, considering that most 
studies have a short follow up. Assisted reproduc-
tive techniques were not so frequently used many 
years ago, as they are today. As these cancers are 
relatively rare, randomized trials would not be 
practical. Most studies are old or case-control, 
and the risk of selection bias may contribute to 
the uncertainty about this relationship. Cohort 
studies can potentially minimize selection bi-
as, but may be limited by recall bias and/or the 
ability to precisely identify and quantitate expo-
sure. In addition, infertility patients may undergo 
more surveillance and so a detection bias could 
increase the real risk. Other methodological prob-
lems include improper or lack of controls, multi-
ple causes and different treatments of infertility. 
Therefore, the net effect of fertility drugs per se is 
very difficult to be properly evaluated93. Another 
limitation for the interpretation of the net effect 
on cancer risk from ART treatments is the lack 
of distinction on the type of drugs used whether 
antiestrogens (like clomiphene or tamoxifen or 
aromatase inhibitors) or gonadotrophins and the 
interindividual differences in ovarian reserve and 
response to fertility drugs due to pathological 
conditions or previous treatments94. Progesterone 
is given to support the luteal phase for at least two 
weeks until the pregnancy test and if confirmed, 
it is continued for an average of 8 more weeks. 
The risk of breast cancer of natural progesterone 
in pre menopause is controversial, it may be neu-
tral or it could even be protective95. In conclusion, 
physicians involved in fertility treatments can 
counsel patients that their use is not associated 
with a significant cancer risk. Table II summariz-
es the main results and could be used as a guide-
line or support for this discussion. At the same 
time clinicians and researchers must consider 
that data are still limited and obtained principally 
from observational cohort and case–control stud-
ies with the above mentioned several method-
ological issues. Infertility per se is a recognized 
risk factor for female cancers including breast, 
endometrial and invasive ovarian cancer. In these 
instances, fertility counseling is a very good 
opportunity to improve those lifestyle factors 
that could affect both fertility and cancer risk: 
like weight, diet, smoking and physical activity. 
Clomiphene, especially when using doses great-
er than 2000 mg and for more than six cycles, 
could modestly increase endometrial cancer risk. 
However, this increase is likely due to common 
characteristics of users (PCOS and overweight) or 
to the need of repetitive cycles in clomiphene re-
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sistant cases. Some studies have found that there 
is a small increased risk that borderline ovarian 
cancer could develop, however the absolute risk 
is small. There is not enough evidence to sug-
gest that there is an association between fertility 
medication use and cancers of the cervix, thy-
roid and colon or melanoma. Additional studies 
with longer follow-up are needed to determine 
Table II. Ovulation induction drugs, possible effects on the risk of cancer risk and implications for patients and physicians.
 Breast cancer  Endometrial cancer  Ovarian cancer  Other cancers 
Clomiphene  No association  No association with an No meaningful increase No increase in the
 with an increase in increase in risk of in the risk of invasive risk of cervical
 the risk of breast endometrial cancer. ovarian cancer.  cancer. 
 cancer. (Grade B)  (Grade B)  (Grade B) (Grade B)
  Some biased evidence of Invasive ovarian cancer risk No increase in the
  maybe increased risk for is not different with one risk of invasive
  total dose > 2000 mg and fertility drug compared thyroid cancer. 
  > 7 number of cycles  to another. (Grade B)  (Grade B) 
    No associated with 
    an increase in the 
    risk of melanoma. 
    (Grade C) 
    No increase in the 
    risk of colon cancer. 
    (Grade B) 
    Not associated with 
    an increase in the 
    risk of lymphoma. 
    (Grade C) 
Gonado  No association with  No association with an No meaningful increase Maybe neutral as
trophins an increase in the risk increase in the risk of in the risk of invasive above.
  of breast cancer.  endometrial cancer.  ovarian cancer. 
 (Grade B)  (Grade B) but cause (Grade B) 
  high estrogen levels  Invasive ovarian cancer  
   risk is not different with one 
   fertility drug compared to 
   another. (Grade B)  
Progesterone  Maybe neutral Highly protective - Maybe neutral (or reduced)  Inconclusive
 (or controversial)   greatly reduced risk   evidence 
Quality of  Limited and Limited and principally Limited and principally Limited and
evidence principally from  some observational from observational studies principally come
 observational studies  studies (Level 2-2 or lower). observational studies
 (Level 2-2 or lower). (Level 2-2 or lower).  (Level 2-2 or lower)
    Sometimes few 
    anedoctal cases 
Main  Infertility per se is a Infertility per se is a Infertility per se is a Poor literature data
literature significant factor of significant factor of risk significant factor of on cervical, thyroid, 
bias risk (nulliparity, later  (nulliparity, later risk (nulliparity,  melanoma, colon
 pregnancies, BRCA?) pregnancies, lower  later pregnancies, cancer and
  (Grade B)  hormonal contraception lower hormonal lymphoma *Same
 Methodological issues use; Lynch?) (Grade B);  contraception use; BRCA?)  methodological
 include heterogeneous  women who require (Grade B) issues 
 treatment regimens,  clomiphene are mostly Detection and surveillance 
 small sample sizes,  anovulatory PCOS and bias for borderline 
 inadequate information  or obese (associated with ovarian cancers that arise 
 regarding duration and  endometrial cancer and in fertile age. 
 dose of treatment,  clomiphene use). *Same methodological 
 retrospective analyses,  Gonadotrophins increase issues 
 and short follow-up estrogen levels, are more  
 periods.*   recently used, and have   
  short follow-up. *Same   
  methodological issues    
Table continued
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whether particular subgroups of women have an 
increased risk of developing cancer following 
fertility treatment. At this time, there is no rea-
son for concern when using assisted reproductive 
techniques. Nonetheless, infertility consultation 
is a good opportunity to address lifestyle changes 
and cancer prevention strategies. 
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Table II (Cont.) Ovulation induction drugs, possible effects on the risk of cancer risk and implications for patients and physicians.
 Breast cancer  Endometrial cancer  Ovarian cancer  Other cancers 
What to tell  Breast cancers are Infertile women with No meaningful increase Available literature
patients caused by a multitude PCOS and those in the risk of invasive is globally
before of genetic and  overweight should mostly ovarian cancer following reassuring about
ART environmental causes:  improve lifestyle the usage of fertility fertility drugs risk
 the net effect of ART is (exercise, weight drugs in infertile on cervical, thyroid, 
 neutral or negligible.  reduction) with women. (Grade B) melanoma, colon
 Renouncing to ART  or without ART Absolute increase in cancer and
 because of the risk of  Renouncing to ART because the risk of borderline lymphoma
 cancer (in estrogen  of the risk of endometrial ovarian tumors is small, Follow code against
 sensitive breast cancer  cancer is not effective or as they are indolent and cancer
 survivors low estrogen pregnancy, or an earlier generally have a favorable recommendations
 increasing regimens with  one, and maybe lactation prognosis. (Grade B)
 letrozole seem safer) are protective. Follow Renouncing to ART because
 is not effective or even code against cancer  of ovarian, or borderline ovarian,  
 counter-effective as  recommendations  cancer risk is not effective or  
 pregnancy, or an earlier   even countereffective.  
 and lactation are   Follow code against cancer  
 protective. Follow code  recommendations*     
 against cancer   
 recommendations    
Implications Fertility drugs Fertility drugs should There is not enough evidence Clomiphene should
for doctors  should not be denied  not be denied or to recommend be used when
 or restricted because restricted because of against using fertility necessary (World
  of the risk of cancer,  cancer risk.  medications to avoid Health Organization
 (with the possible  Clomiphene should be borderline ovarian tumors. Group II ovulation
 exception of lower used when necessary (ASRM recommendation) disorders) as it has
  estrogen increasing or (World Health There is insufficient consisten been related with
  letrozole, regimens in  Organization Group II t evidence that a particular thyroid cancer in
 already breast cancer ovulation disorders) fertility drug increases the some studies
  patients    risk of borderline ovarian  
   tumors. (Grade C) Inform 
   of the possible small risk using  
   absolute numbers of low- 
   malignant potential cancers, and  
   their favorable prognosis 
   (ASRM recommendation)  
What to do  History History History History Pap smear 
before ART (BRCA (Lynch, BRCA) (BRCA; Lynch) Check thyroid
treatment  Lynch)  Thorough diagnostic Thorough diagnostic function
 Breast ultrasound  workup of any workup of any suspicious (ultrasound?)
 Mammography suspicious endometrial (laparoscopy) adnexal mass 
  (> 38 years old?)  lesion (ultrasound,  (Ultrasound, CA 125 + HE4 
  Hysteroscopy, Sono  magnetic resonance and/or 
  Hysteroscopy)  laparoscopy)   
Which  Breast ultrasound Endometrial ultrasound Thorough diagnostic Check thyroid
follow up  Mammography Hysteroscopy and workup of any suspicious function?? 
after ART   (closer follow up?)  Biopsy if a suspicious  adnexal mass (ultrasound?) 
  bleeding or uterine (closer follow up?) 
   abnormal image  Long term follow up 
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